Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions

In this article, the authors review the current state of fibroblast activation protein (FAP)-targeted interventions utilizing available data from clinicaltrials.gov. Thirty-seven records were reviewed and demonstrated interventions with imaging studies comprising the largest portion of the active st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PET clinics Ročník 18; číslo 3; s. 429
Hlavní autoři: Mosessian, Sherly, Jensen, Jessica D, Enke, Aaron S
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.07.2023
Témata:
Diagnostic Imaging
Fibroblasts - metabolism
Humans
Cancer-associated fibroblasts
Clinical development
Theranostic
Clinical trial
Diagnostic
Radioligand therapy
Radiopharmaceuticals
Fibroblast activation protein
ISSN:1879-9809, 1879-9809
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In this article, the authors review the current state of fibroblast activation protein (FAP)-targeted interventions utilizing available data from clinicaltrials.gov. Thirty-seven records were reviewed and demonstrated interventions with imaging studies comprising the largest portion of the active studies in progress, followed by therapeutic studies using non-radioligand and radioligand therapy. The efforts are in early stages of clinical development; however the field is gaining significant momentum. Completion of existing clincial studies and entrance of new products into the clincial trial phase will shed important light on the clinical utility of these interventions and shape future clinical development efforts.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1879-9809
1879-9809
DOI:10.1016/j.cpet.2023.02.010